Molecular "tweezers" pick apart bacterias' biofilm

By plucking out peptides, the tweezers can destroy the drug and immune system blocking shield.

An incredibly tiny version of your grooming tool may become a new weapon against bacteria. Alongside German and American partners, researchers at Israel’s Ben-Gurion University (BGU) have developed a set of “molecular tweezers” that take aim at the biofilm that protects bacteria, The Jerusalem Post reports.

“The success of the study in damaging biofilm using molecular tweezers indicates an innovative direction of antibiotic treatments against pathogenic bacteria without concerns of developing resistance,” Raz Jelinek, vice president and dean for research and development at BGU, told the Post.

Antimicrobial armor: A biofilm is formed when a group of cells form a protective barrier on a surface; in the case of bacteria, these biofilms can provide an effective shield from antibiotics, creating a unique, and sometimes dramatic, form of antimicrobial resistance — they don’t go down easy.

Biofilm bacteria have been found on all manner of medical implants, including “prosthetic heart valves, orthopedic implants, intravascular catheters, artificial hearts, left ventricular assist devices, cardiac pacemakers, vascular prostheses, cerebrospinal fluid shunts, urinary catheters, ocular prostheses and contact lenses, and intrauterine contraceptive devices.”

Once a biofilm-protected bacterial infection sets in, the consequences can be devastating, as the protected bacteria wreak havoc safely ensconced from antibiotics and our immune system.

A biofilm to pick: Biofilms are made, in part, by tiny fibers. It’s those little support structures that Jelinek, the study lead, and student Ravit Malishev took aim at.

“The tweezers are just like your home tweezers but a million times smaller, and instead of plucking hairs they attack fibers of the bacteria’s biofilm,” Jelinek told Americans for Ben-Gurion University, relayed by EurekAlert!

In their study, published in Cell Chemical Biology, the researchers turned the tweezers loose on Staphylococcus aureus, the notorious bug behind Staph infections.

The tweezers impact a special peptide that Staph secretes that acts as a biofilm scaffolding, the researchers write. By inhibiting the peptide’s ability to form biofilms, the tweezers weaken and break the biofilm, allowing the immune system and/or antibiotics to take the fight to the Staph, proof-of-concept for molecular tweezers potentially becoming part of our infection-fighting arsenal.

“In fact, this is the first time it has been shown that biofilm formation can be prevented and existing biofilm destroyed by molecular tweezers,” Jelinek told The Jerusalem Post.

It took three years for the researchers to tease out how exactly the molecular tweezers were picking apart the biofilms, Malishev told the Post. 

Because the tweezers mechanically attack the biofilm, and not the bacteria itself, the method doesn’t lend itself to evolving resistance.

Getting from here to hospitals: It’s a haul from proof-of-concept against one bacteria — albeit it a common one, which causes lots of problems — and tearing biofilms apart like fashion police on the Met carpet. Jelinek envisions someday people being able to swallow the tiny tweezers, which will then find their way to the biofilm and get to work.

“This breakthrough may open up new ways to fight antibiotic-resistant bacteria,” Malishev said.

We’d love to hear from you! If you have a comment about this article or if you have a tip for a future Freethink story, please email us at [email protected].

Related
In a future with brain-computer interfaces like Elon Musk’s Neuralink, we may need to rethink freedom of thought
In a future with more “mind reading,” thanks to computer-brain interfaces, we may need to rethink freedom of thought.
Personalized cancer vaccines are having a moment
Personalized cancer vaccines were a recurring theme at the annual meeting of the American Association for Cancer Research in 2024.
When an antibiotic fails: MIT scientists are using AI to target “sleeper” bacteria
Most antibiotics target metabolically active bacteria, but AI can help efficiently screen compounds that are lethal to dormant microbes.
What’s next for COVID-19 drugs?
Paxlovid may have underperformed in a new trial, but other promising COVID-19 drugs are being authorized or in the works.
Old drug appears to halt progression of Parkinson’s motor symptoms
A GLP-1 agonist used to treat diabetes appeared to halt the progression of Parkinson’s symptoms in a phase 2 trial.
Up Next
gene therapy
Subscribe to Freethink for more great stories